ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VIR Vir Biotechnology Inc

8.76
-0.11 (-1.24%)
29 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vir Biotechnology Inc NASDAQ:VIR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11 -1.24% 8.76 8.75 9.16 8.97 8.76 8.92 2,361,142 01:00:00

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

23/05/2024 9:05pm

Business Wire


Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Vir Biotechnology Charts.

Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.

Vir Biotechnology’s stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2024 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at www.virtualshareholdermeeting.com/VIR2024. Online access to the Annual Meeting will begin at 8:45 a.m. PT on May 29, 2024. Stockholders should allow ample time for the check-in procedures.

Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Media Carly Scaduto Senior Director, External Communications cscaduto@vir.bio +1 314-368-5189

Investors Richard Lepke Senior Director, Investor Relations rlepke@vir.bio +1 978-973-9986

1 Year Vir Biotechnology Chart

1 Year Vir Biotechnology Chart

1 Month Vir Biotechnology Chart

1 Month Vir Biotechnology Chart